NFKB1 and neoplasm: Cold plasma cancer cell therapy exploits this mechanism by driving ROS to trigger cleavage of Hsp90 chaperones and degradation of PKD2, which further stabilizes HIF-1α and activates NF-κB and VEGFA, and subsequent tissue vascularization to promote tumor angiogenesis.62, 63, 64 This reveals that despite targeting the same protein, distinct mechanisms govern cancerous cell progression.